NYSE:TEVA - Teva Pharmaceutical Industries Stock Price, Price Target & More

Question 1

What is Teva Pharmaceutical Industries' stock symbol?

Answer

Teva Pharmaceutical Industries trades on the New York Stock Exchange (NYSE) under the ticker symbol "TEVA."

Question 2

How often does Teva Pharmaceutical Industries pay dividends? What is the dividend yield for Teva Pharmaceutical Industries?

Answer

Teva Pharmaceutical Industries announced a quarterly dividend on Thursday, November 2nd. Shareholders of record on Tuesday, November 28th will be given a dividend of $0.085 per share on Tuesday, December 12th. This represents a $0.34 annualized dividend and a yield of 1.57%. The ex-dividend date of this dividend is Monday, November 27th. View Teva Pharmaceutical Industries' Dividend History.

Question 3

How were Teva Pharmaceutical Industries' earnings last quarter?

Answer

Teva Pharmaceutical Industries (NYSE:TEVA) issued its quarterly earnings data on Thursday, May, 3rd. The company reported $0.91 EPS for the quarter, topping analysts' consensus estimates of $0.63 by $0.28. The company had revenue of $5.07 billion for the quarter, compared to analysts' expectations of $4.80 billion. Teva Pharmaceutical Industries had a positive return on equity of 18.59% and a negative net margin of 72.36%. Teva Pharmaceutical Industries's quarterly revenue was down 10.0% on a year-over-year basis. During the same period last year, the business earned $1.06 earnings per share. View Teva Pharmaceutical Industries' Earnings History.

Question 4

When is Teva Pharmaceutical Industries' next earnings date?

Answer

Teva Pharmaceutical Industries is scheduled to release their next quarterly earnings announcement on Thursday, August, 2nd 2018. View Earnings Estimates for Teva Pharmaceutical Industries.

Question 5

What guidance has Teva Pharmaceutical Industries issued on next quarter's earnings?

Answer

Teva Pharmaceutical Industries updated its FY18 earnings guidance on Thursday, May, 3rd. The company provided earnings per share guidance of $2.40-2.65 for the period, compared to the Thomson Reuters consensus EPS estimate of $2.42. The company issued revenue guidance of $18.5-19.0 billion, compared to the consensus revenue estimate of $18.62 billion.

Question 6

What price target have analysts set for TEVA?

Answer

27 analysts have issued twelve-month price targets for Teva Pharmaceutical Industries' stock. Their forecasts range from $11.00 to $41.00. On average, they expect Teva Pharmaceutical Industries' stock price to reach $20.0577 in the next year. View Analyst Ratings for Teva Pharmaceutical Industries.

Question 7

What are Wall Street analysts saying about Teva Pharmaceutical Industries stock?

Answer

Here are some recent quotes from research analysts about Teva Pharmaceutical Industries stock:

1. According to Zacks Investment Research, "Teva beat estimates for both earnings and sales in the first quarter and also raised its 2018 outlook. Teva is facing significant challenges in the form of accelerated generic competition for Copaxone, new competition for branded products, pricing erosion in the U.S. generics business, lower-than-expected contribution from new generic launches and a massive debt load. Nonetheless, Teva has a new organizational structure in place, is closing plants, cutting down its generics portfolio, divesting non-core assets, eliminating low-value R&D projects, and aims to cut its global workforce by more than 25% over the next two years to revive growth. Its financial position seems more stable than before as it is regularly paying down debt. After declining sharply in 2017, Teva’s shares have also picked up this year. However, Teva has a long way to go before gaining stability and resumption of organic growth seems unlikely before 2019." (5/9/2018)
2. Maxim Group analysts commented, "Teva reported a better than expected quarter at $5.5B in revenues versus consensus at $5.3B, but we note revenues were down sequentially (3Q17: $5.6B). Generics came in at $3.1B and higher margin specialty at $1.8B. Copaxone in particular outperformed expectations, generating $821M, which is 34% greater than the $611M expected by the street. The beat on revenues followed through to non-GAAP EPS, which was $0.93, above expectations of $0.77." (2/8/2018)
3. Cantor Fitzgerald analysts commented, "This morning Teva announced more details of its new strategic plan under CEO Kare Schultz, including the layoff of 14,000 people. This is meaningfully above the Street’s estimate of 10,000 jobs." (12/14/2017)

Question 8

Are investors shorting Teva Pharmaceutical Industries?

Answer

Teva Pharmaceutical Industries saw a increase in short interest in the month of May. As of May 15th, there was short interest totalling 53,599,101 shares, an increase of 0.3% from the April 30th total of 53,782,387 shares. Based on an average daily trading volume, of 16,116,685 shares, the short-interest ratio is currently 3.3 days.

Question 9

Who are some of Teva Pharmaceutical Industries' key competitors?

Answer

Some companies that are related to Teva Pharmaceutical Industries include Bristol-Myers Squibb (BMY), Celgene (CELG), Allergan (AGN), Shire (SHPG), Zoetis (ZTS), Vertex Pharmaceuticals (VRTX), Takeda Pharmaceutical (TKPYY), Regeneron (REGN), Astellas Pharma (ALPMY), Shiseido (SSDOY), Alexion Pharmaceuticals (ALXN), Mylan (MYL), BioMarin Pharmaceutical (BMRN), Grifols (GRFS) and UCB (UCBJF).

Question 10

Who are Teva Pharmaceutical Industries' key executives?

Answer

Teva Pharmaceutical Industries' management team includes the folowing people:

Mr. Michael McClellan, Exec. VP & CFO (Age 47)
Dr. Carlo de Notaristefani, Exec. VP of Global Operations (Age 60)
Mr. Mark Sabag, Exec. VP of Global HR (Age 47)
Dr. Hafrun Fridriksdottir, Exec. VP of Global R&D (Age 56)
Mr. Kåre Schultz, Pres, Chief Exec. Officer & Director (Age 57)

Question 11

Has Teva Pharmaceutical Industries been receiving favorable news coverage?

Answer

News coverage about TEVA stock has trended positive on Friday, Accern Sentiment Analysis reports. The research group ranks the sentiment of media coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Teva Pharmaceutical Industries earned a coverage optimism score of 0.33 on Accern's scale. They also gave press coverage about the company an impact score of 45.35 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the next few days.

Question 12

Who are Teva Pharmaceutical Industries' major shareholders?

Answer

Teva Pharmaceutical Industries' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Franklin Resources Inc. (7.19%), Polaris Capital Management LLC (0.97%), OppenheimerFunds Inc. (0.42%), Thornburg Investment Management Inc. (0.37%), Swiss National Bank (0.33%) and Barrow Hanley Mewhinney & Strauss LLC (0.28%). Company insiders that own Teva Pharmaceutical Industries stock include Brendan P O'grady, Deborah A Griffin, Mark Sabag, Michael James Mcclellan, Richard Daniell, Roberto Mignone and Sven Dethlefs. View Institutional Ownership Trends for Teva Pharmaceutical Industries.

Question 13

Which institutional investors are selling Teva Pharmaceutical Industries stock?

Answer

TEVA stock was sold by a variety of institutional investors in the last quarter, including Franklin Resources Inc., Millennium Management LLC, Schroder Investment Management Group, Psagot Investment House Ltd., Clal Insurance Enterprises Holdings Ltd, State of Wisconsin Investment Board, Bellevue Group AG and Sei Investments Co.. Company insiders that have sold Teva Pharmaceutical Industries company stock in the last year include Brendan P O'grady, Deborah A Griffin, Mark Sabag, Michael James Mcclellan, Richard Daniell and Sven Dethlefs. View Insider Buying and Selling for Teva Pharmaceutical Industries.

Question 14

Which institutional investors are buying Teva Pharmaceutical Industries stock?

Answer

TEVA stock was bought by a variety of institutional investors in the last quarter, including Thornburg Investment Management Inc., Polaris Capital Management LLC, Caisse DE Depot ET Placement DU Quebec, OppenheimerFunds Inc., Susquehanna Fundamental Investments LLC, CIBC World Markets Inc., New York State Common Retirement Fund and Natixis. View Insider Buying and Selling for Teva Pharmaceutical Industries.

Question 15

How do I buy shares of Teva Pharmaceutical Industries?

Answer

Shares of TEVA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

Question 16

What is Teva Pharmaceutical Industries' stock price today?

Answer

One share of TEVA stock can currently be purchased for approximately $21.63.

Question 17

How big of a company is Teva Pharmaceutical Industries?

Answer

Teva Pharmaceutical Industries has a market capitalization of $21.51 billion and generates $22.39 billion in revenue each year. The company earns $-16,265,000,000.00 in net income (profit) each year or $3.93 on an earnings per share basis. Teva Pharmaceutical Industries employs 51,792 workers across the globe.

Question 18

How can I contact Teva Pharmaceutical Industries?

Answer

Teva Pharmaceutical Industries' mailing address is 5 BAZEL ST P O B 3190, PETACH TIKVA L3, 49131. The company can be reached via phone at 972-3926-7267 or via email at [email protected]

Community Ranking:		2.6 out of 5 ( )
Outperform Votes:		976 (Vote Outperform)
Underperform Votes:		871 (Vote Underperform)
Total Votes:		1,847

	Today	30 Days Ago	90 Days Ago	180 Days Ago
Consensus Rating:	Hold	Hold	Hold	Hold
Consensus Rating Score:	1.96	1.96	1.96	2.04
Ratings Breakdown:	7 Sell Rating(s) 14 Hold Rating(s) 6 Buy Rating(s) 0 Strong Buy Rating(s)	7 Sell Rating(s) 14 Hold Rating(s) 6 Buy Rating(s) 0 Strong Buy Rating(s)	7 Sell Rating(s) 15 Hold Rating(s) 6 Buy Rating(s) 0 Strong Buy Rating(s)	5 Sell Rating(s) 16 Hold Rating(s) 6 Buy Rating(s) 0 Strong Buy Rating(s)
Consensus Price Target:	$20.0577	$20.0192	$21.1750	$21.3704
Price Target Upside:	7.27% downside	12.34% upside	12.99% upside	55.99% upside

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
5/24/2018	Barclays	Set Price Target	Equal Weight ➝ Hold	$13.00 ➝ $20.00	Medium
5/17/2018	Cantor Fitzgerald	Set Price Target	Hold	$18.00	Low
5/14/2018	Credit Suisse Group	Set Price Target	Buy	$23.00	Low
5/7/2018	Oppenheimer	Reiterated Rating	Hold		Low
5/7/2018	Morgan Stanley	Reiterated Rating	Equal Weight ➝ Hold	$18.00	Low
5/3/2018	Maxim Group	Reiterated Rating	Hold		Low
4/22/2018	Wells Fargo & Co	Set Price Target	Sell	$17.00	Low
4/20/2018	Mizuho	Reiterated Rating	Buy	$27.00	Low
3/26/2018	Royal Bank of Canada	Reiterated Rating	Hold	$16.00	Low
3/20/2018	Jefferies Group	Initiated Coverage	Hold ➝ Hold	$19.00	Medium
2/9/2018	Bank of America	Lower Price Target	Underperform ➝ Underperform	$17.00 ➝ $16.00	Low
2/9/2018	Leerink Swann	Lower Price Target	Underweight ➝ Underperform	$17.00 ➝ $16.00	High
2/9/2018	Deutsche Bank	Lower Price Target	Hold ➝ Hold	$20.00 ➝ $18.00	Medium
2/9/2018	Gabelli	Downgrade	Buy ➝ Hold	$19.00	Medium
2/9/2018	Piper Jaffray Companies	Downgrade	Neutral ➝ Underweight	$11.00	Medium
2/2/2018	BTIG Research	Downgrade	Neutral ➝ Sell	$17.00	Low
1/25/2018	Susquehanna Bancshares	Reiterated Rating	Positive ➝ Positive	$22.00 ➝ $24.00	Medium
1/11/2018	Goldman Sachs Group	Boost Price Target	Buy	$20.00 ➝ $25.00	High
1/4/2018	Citigroup	Upgrade	Neutral ➝ Buy	$24.00	Low
12/18/2017	UBS	Set Price Target	Hold	$12.00 ➝ $20.00	Low
12/12/2017	Guggenheim	Initiated Coverage	Neutral ➝ Neutral	$16.00	High
11/13/2017	JPMorgan Chase & Co.	Downgrade	Neutral ➝ Underweight	$11.48 ➝ $11.00	N/A
10/25/2017	Evercore ISI	Set Price Target	Buy	$38.00	N/A
10/4/2017	Cowen	Reiterated Rating	Market Perform	$30.00 ➝ $18.00	N/A
9/21/2017	Sanford C. Bernstein	Lower Price Target	Mkt Perform ➝ Market Perform	$28.00 ➝ $20.00	Low
9/6/2017	JMP Securities	Boost Price Target	Underperform	$13.00 ➝ $14.00	Low
8/3/2017	CIBC	Reiterated Rating	Outperform ➝ Market Perform		High
2/28/2017	Argus	Downgrade	Buy ➝ Hold	$59.35 ➝ $31.90	N/A
9/29/2016	OTR Global	Initiated Coverage	Positive		N/A

Quarter	Number of Estimates	Low Estimate	High Estimate	Average Estimate
Q1 2018	2	$0.58	$0.63	$0.61
Q2 2018	3	$0.52	$0.68	$0.60
Q3 2018	3	$0.49	$0.55	$0.52
Q4 2018	3	$0.37	$0.51	$0.46

Date	Quarter	Consensus Estimate	Actual EPS	Revenue Estimate	Actual Revenue	Release Link	Conference Call
8/2/2018
5/3/2018	3/31/2018	$0.63	$0.91	$4.7992 billion	$5.0650 billion	View	N/A
2/8/2018	Q4 17	$0.77	$0.91	$5.2870 billion	$5.4590 billion	View	Listen
11/2/2017	Q3 2017	$1.03	$0.95	$5.6065 billion	$5.61 billion	View	N/A
8/3/2017	6/30/2017	$1.06	$0.99	$5.7168 billion	$5.6860 billion	View	Listen
5/11/2017	Q1 17	$1.06	$1.06	$5.6885 billion	$5.63 billion	View	N/A
2/13/2017	Q416	$1.36	$1.38	$6.26 billion	$6.25 billion	View	N/A
11/15/2016	Q316	$1.29	$1.31	$5.7132 billion	$5.56 billion	View	N/A
8/4/2016	Q216	$1.20	$1.25	$4.86 billion	$5.00 billion	View	N/A
5/9/2016	Q116	$1.17	$1.20	$4.78 billion	$4.81 billion	View	N/A
2/11/2016	Q415	$1.29	$1.28	$4.83 billion	$4.88 billion	View	Listen
10/29/2015	Q315	$1.28	$1.35	$4.75 billion	$4.80 billion	View	Listen
7/30/2015	Q215	$1.31	$1.43	$4.90 billion	$4.97 billion	View	Listen
4/30/2015	Q115	$1.26	$1.36	$4.84 billion	$5.00 billion	View	N/A
2/5/2015	Q414	$1.31	$1.31	$5.17 billion	$5.17 billion	View	N/A
10/30/2014	Q314	$1.23	$1.32	$5.09 billion	$5.06 billion	View	N/A
7/31/2014	Q214	$1.21	$1.23	$5.08 billion	$5.00 billion	View	N/A
5/1/2014	Q114	$1.22	$1.22	$5.11 million	$5.00 billion	View	N/A
2/6/2014	Q413	$1.26	$1.42	$5.19 billion	$5.40 billion	View	N/A
10/31/2013	Q313	$1.26	$1.27	$5.00 billion	$5.0590 billion	View	N/A
8/1/2013	Q213	$1.20	$1.20	$4.94 billion	$4.90 billion	View	N/A
5/2/2013	Q113	$1.10	$1.12	$4.85 billion	$4.90 billion	View	N/A
2/7/2013	Q412	$1.33	$1.32	$5.26 billion	$5.20 billion	View	N/A
11/1/2012	Q312	$1.25	$1.28	$5.08 billion	$5.00 billion	View	N/A
8/2/2012		$1.28	$1.28			View	N/A
5/9/2012		$1.44	$1.47			View	N/A
2/15/2012		$1.58	$1.59			View	N/A
11/2/2011		$1.22	$1.25			View	N/A
7/27/2011		$1.08	$1.10			View	N/A
5/11/2011		$1.03	$1.04			View	N/A
2/8/2011		$1.28	$1.25			View	N/A
11/2/2010	Q3 2010	$1.27	$1.30			View	N/A
7/26/2010	Q2 2010	$1.04	$1.08			View	N/A
5/4/2010	Q1 2010	$0.89	$0.92			View	N/A
2/16/2010	Q4 2009	$0.95	$0.94			View	N/A
11/3/2009	Q3 2009	$0.88	$0.89			View	N/A
7/28/2009	Q2 2009	$0.80	$0.83			View	N/A
5/5/2009	Q1 2009	$0.67	$0.72			View	N/A
2/17/2009	Q4 2008	$0.73	$0.76			View	N/A
11/6/2008	Q3 2008	$0.69	$0.72			View	N/A
7/29/2008	Q2 2008	$0.64	$0.65			View	N/A
5/6/2008	Q1 2008	$0.63	$0.64			View	N/A
2/12/2008	Q4 2007	$0.66	$0.69			View	N/A

Most Recent Dividend:	12/12/2017
Annual Dividend:	$0.43
Dividend Yield:	1.99%
Dividend Growth:	-14.40% (3 Year Average)
Payout Ratio(s):	10.94% (Trailing 12 Months of Earnings) 17.55% (Based on This Year's Estimates) 17.48% (Based on Next Year's Estimates) 6.72% (Based on Cash Flow)
Frequency:	Quarterly Dividend

Announced	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
11/2/2017	quarterly	$0.0850	2.74%	11/27/2017	11/28/2017	12/12/2017
8/7/2017	quarterly	$0.0850	1.83%	8/25/2017	8/29/2017	9/14/2017
5/11/2017	quarterly	$0.34	4.28%	6/1/2017	6/5/2017	6/22/2017
2/13/2017	quarterly	$0.34	3.7%	2/28/2017	3/2/2017	3/20/2017
11/15/2016	quarterly	$0.34		12/1/2016	12/5/2016	12/20/2016
8/4/2016	quarterly	$0.34		8/18/2016	8/22/2016	9/8/2016
5/9/2016	quarterly	$0.34		5/20/2016	5/24/2016	6/7/2016
2/16/2016	Quarterly	$0.2890		2/25/2016	2/29/2016	3/14/2016
10/29/2015	quarterly	$0.34		11/13/2015	11/17/2015	12/3/2015
7/30/2015	quarterly	$0.34		8/18/2015	8/20/2015	9/3/2015
5/5/2015	special	$0.34	2.25%	5/15/2015	5/19/2015	6/4/2015
2/5/2015	quarterly	$0.34	2.36%	2/17/2015	2/19/2015	3/3/2015
10/31/2014	special	$0.3210	2.43%	11/13/2014	11/17/2014	12/2/2014
8/1/2014	quarterly	$0.3530	2.61%	8/19/2014	8/21/2014	9/4/2014
5/2/2014	quarterly	$0.3470	2.77%	5/16/2014	5/20/2014	6/2/2014
2/4/2014		$0.34		2/20/2014	2/24/2014	3/10/2014
11/1/2013	quarterly	$0.3260	3.51%	11/18/2013	11/20/2013	12/2/2013
8/5/2013	quarterly	$0.3220	3.34%	8/16/2013	8/20/2013	9/3/2013
8/1/2013	quarterly	$0.3220			8/20/2013	9/2/2013
5/6/2013	special	$0.32	3.28%	5/16/2013	5/20/2013	6/3/2013
2/8/2013	quarterly	$0.31	3.21%	2/19/2013	2/21/2013	3/7/2013

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
5/10/2018	Roberto Mignone	Director	Buy	750,000	$19.24	$14,430,000.00
3/19/2018	Deborah A Griffin	Insider	Sell	943	$17.88	$16,860.84
3/19/2018	Michael James Mcclellan	CFO	Sell	287	$17.88	$5,131.56
3/19/2018	Richard Daniell	VP	Sell	1,297	$17.89	$23,203.33	1,297
3/19/2018	Sven Dethlefs	EVP	Sell	571	$17.88	$10,209.48	5,016
3/5/2018	Brendan P O'grady	EVP	Sell	705	$19.38	$13,662.90
3/5/2018	Deborah A Griffin	Insider	Sell	773	$19.38	$14,980.74
3/5/2018	Richard Daniell	VP	Sell	1,108	$19.28	$21,362.24
2/15/2018	Mark Sabag	EVP	Sell	5,050	$19.68	$99,384.00	44,517

Date	Headline
	FDA Confirms September Action Date for Teva's Migraine Drug www.msn.com - May 25 at 8:04 AM
	Global Erythropoietin (EPO) Drugs Market Growth Opportunities: Teva Pharmaceutical Industries Ltd, Pfizer Inc www.marketwatch.com - May 25 at 8:04 AM
	Teva Pharmaceutical Industries (TEVA) PT Raised to $20.00 www.americanbankingnews.com - May 24 at 2:07 PM
	TXMD Awaits Big Day Next Week, TEVA Faces FDA In Sep., ESPR On Watch www.nasdaq.com - May 24 at 8:04 AM
	Teva hopes to launch migraine drug as soon as September www.reuters.com - May 24 at 8:04 AM
	Cramer's lightning round: I don't have a thesis for Blue Apron, so don't buy finance.yahoo.com - May 24 at 8:04 AM
	BRIEF-Teva Confirms September PDUFA Date For Fremanezumab www.reuters.com - May 23 at 5:47 PM
	Teva Pharma (TEVA) Fremanezumab PDUFA Date Extended Until September www.streetinsider.com - May 23 at 5:47 PM
	Teva Confirms September PDUFA Date for Fremanezumab finance.yahoo.com - May 23 at 8:07 AM
	Bile Duct Cancer Market Latest Industry Scenario, Trends, Share & Future Forecas 2017 – 2023 www.marketwatch.com - May 21 at 5:22 PM
	Osgood-Schlatter Market – Overall Industry Analysis during forecast period 2017-2023 www.marketwatch.com - May 19 at 8:01 AM
	Parathyroid Disorders Market Trend, Segmentation And Industry Analysis Research Report 2018-2023 www.marketwatch.com - May 19 at 8:01 AM
	Cantor Fitzgerald Reiterates "$18.00" Price Target for Teva Pharmaceutical Industries (TEVA) www.americanbankingnews.com - May 18 at 4:17 PM
	Buffett Gets Even Greedier With Teva Pharmaceuticals. Time to Buy? finance.yahoo.com - May 18 at 8:10 AM
	Free Stock Performance Review on Teva Pharma and Three Other Healthcare Sector finance.yahoo.com - May 18 at 8:10 AM
	Warren Buffett Pushing More Cash To Equities; 'Big 5' Stocks Still At The Top finance.yahoo.com - May 17 at 8:03 AM
	Teva’s Fiscal Guidance: Confidence in Its Growth finance.yahoo.com - May 17 at 8:03 AM
	Teva Shares Jump After Warren Buffett Doubles Stake in Drugmaker www.thestreet.com - May 16 at 6:00 PM
	Teva Stock Higher After Buffett's Bump www.msn.com - May 16 at 6:00 PM
	Teva Pharmaceutical Industries Ltd, Once a Falling Machete, Is Spiking — Chase It investorplace.com - May 16 at 12:21 PM
	Teva Pharmaceutical Industries Ltd, Once a Falling Machete, Is Spiking — Chase It investorplace.com - May 16 at 12:18 PM
	Global Sleeping Aids Market Growth Opportunities: Teva Pharmaceutical Industries Ltd., Sanofi, Compumedics Ltd www.marketwatch.com - May 16 at 8:01 AM
	Buffett Buys More Apple and Teva Shares, Dumps IBM finance.yahoo.com - May 16 at 8:01 AM
	Here's What Warren Buffett Is Buying and Selling finance.yahoo.com - May 16 at 8:01 AM
	How Valeant Pharmaceuticals’ Branded Rx Segment Performed in 1Q18 finance.yahoo.com - May 16 at 8:01 AM
	U.S. state attorneys general sue Purdue Pharma over opioid epidemic www.msn.com - May 15 at 5:59 PM
	Teva shares up 5% on Berkshire's increased stake www.marketwatch.com - May 15 at 5:59 PM
	Berkshire doubles Teva stake, adds to Apple, ends a newspaper bet finance.yahoo.com - May 15 at 5:59 PM
	Buffett's company doubles investment in drugmaker Teva finance.yahoo.com - May 15 at 5:59 PM
	Credit Suisse Group Analysts Give Teva Pharmaceutical Industries (TEVA) a $23.00 Price Target www.americanbankingnews.com - May 15 at 1:07 PM
	Teva up 1% premarket on Perrigo stumble with generic ProAir seekingalpha.com - May 15 at 8:06 AM
	An Overview of Valeant Pharmaceuticals’ Performance in 1Q18 finance.yahoo.com - May 15 at 8:06 AM
	Teva’s Austedo Sales Continue to Gain Momentum in 2018 finance.yahoo.com - May 15 at 8:06 AM
	Generic Drugmakers See Some Relief But May Not Have a Remedy Yet www.bloomberg.com - May 14 at 5:31 PM
	Wall Street Is More Optimistic on Amgen's Next Blockbuster Drug www.bloomberg.com - May 14 at 5:31 PM
	Teva: It Will Get Worse seekingalpha.com - May 14 at 5:31 PM
	Teva Pharmaceutical Industries (TEVA) Receives Consensus Recommendation of "Hold" from Analysts www.americanbankingnews.com - May 14 at 5:31 PM
	Active Pharmaceutical Ingredient (API) Market is Supposed to Reach US$ 219.00 Billion By 2023 www.marketwatch.com - May 14 at 8:06 AM
	Teva’s Restructuring Plan Is on Track finance.yahoo.com - May 14 at 8:06 AM
	Teva Pharmaceutical Industries (TEVA) Director Roberto Mignone Purchases 750,000 Shares www.americanbankingnews.com - May 11 at 7:23 PM
	BRIEF-Teva Canada Announces Launch Of Teva-Cyclosporine Ophthalmic Emulsion www.reuters.com - May 10 at 6:18 PM
	Teva Pharmaceutical Industries to Post Q2 2018 Earnings of $0.68 Per Share, Oppenheimer Forecasts (TEVA) www.americanbankingnews.com - May 10 at 6:25 AM
	Teva Pharmaceutical Industries (TEVA) Expected to Post Quarterly Sales of $4.71 Billion www.americanbankingnews.com - May 10 at 4:44 AM
	Teva Pharmaceutical Industries (TEVA) Upgraded at Zacks Investment Research www.americanbankingnews.com - May 9 at 6:59 PM
	Teva: The Numbers Don't Tell The Whole Story seekingalpha.com - May 9 at 5:53 PM
	Warren Buffett's 10 Big Stock Losers finance.yahoo.com - May 8 at 5:56 PM
	Teva Pharmaceutical Industries (TEVA) Expected to Announce Earnings of $0.65 Per Share www.americanbankingnews.com - May 8 at 10:26 AM
	Global Antidepressant Drugs Market Competitive landscape: Allergan Plc, Takeda Pharmaceutical Co Ltd www.marketwatch.com - May 8 at 8:03 AM
	Teva Pharmaceutical Industries' (TEVA) Hold Rating Reiterated at Oppenheimer www.americanbankingnews.com - May 7 at 7:16 PM
	Why Teva Pharmaceutical Industries, Gramercy Property Trust, and Medtronic Jumped Today www.fool.com - May 7 at 4:32 PM

NYSE:TEVA - Teva Pharmaceutical Industries Stock Price, Price Target & More

About Teva Pharmaceutical Industries (NYSE:TEVA)

Receive TEVA News and Ratings via Email

Industry, Sector and Symbol

Debt

Price-To-Earnings

Sales & Book Value

Profitability

Miscellaneous

Teva Pharmaceutical Industries (NYSE:TEVA) Frequently Asked Questions

What is Teva Pharmaceutical Industries' stock symbol?

How often does Teva Pharmaceutical Industries pay dividends? What is the dividend yield for Teva Pharmaceutical Industries?

How were Teva Pharmaceutical Industries' earnings last quarter?

When is Teva Pharmaceutical Industries' next earnings date?

What guidance has Teva Pharmaceutical Industries issued on next quarter's earnings?

What price target have analysts set for TEVA?

What are Wall Street analysts saying about Teva Pharmaceutical Industries stock?

Are investors shorting Teva Pharmaceutical Industries?

Who are some of Teva Pharmaceutical Industries' key competitors?

Who are Teva Pharmaceutical Industries' key executives?

Has Teva Pharmaceutical Industries been receiving favorable news coverage?

Who are Teva Pharmaceutical Industries' major shareholders?

Which institutional investors are selling Teva Pharmaceutical Industries stock?

Which institutional investors are buying Teva Pharmaceutical Industries stock?

How do I buy shares of Teva Pharmaceutical Industries?

What is Teva Pharmaceutical Industries' stock price today?

How big of a company is Teva Pharmaceutical Industries?

How can I contact Teva Pharmaceutical Industries?

MarketBeat Community Rating for Teva Pharmaceutical Industries (TEVA)

Analyst Ratings

Teva Pharmaceutical Industries (NYSE:TEVA) Price Target and Consensus Rating

Teva Pharmaceutical Industries (NYSE:TEVA) Consensus Price Target History

Teva Pharmaceutical Industries (NYSE:TEVA) Analyst Ratings History

Earnings

Teva Pharmaceutical Industries (NYSE:TEVA) Earnings History and Estimates Chart

Teva Pharmaceutical Industries (NYSE:TEVA) Earnings Estimates

Teva Pharmaceutical Industries (NYSE TEVA) Earnings History by Quarter

Dividends

Teva Pharmaceutical Industries (NYSE:TEVA) Dividend Information

Teva Pharmaceutical Industries (NYSE:TEVA) Dividend History by Quarter

Insider Trades

Teva Pharmaceutical Industries (NYSE TEVA) Insider Trading and Institutional Ownership History

Teva Pharmaceutical Industries (NYSE TEVA) Insider Trading History

Headlines

Teva Pharmaceutical Industries (NYSE TEVA) News Headlines

SEC Filings

Teva Pharmaceutical Industries (NYSE:TEVA) SEC Filings

Social Media

Financials

Teva Pharmaceutical Industries (NYSE:TEVA) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Teva Pharmaceutical Industries (NYSE TEVA) Stock Chart for Friday, May, 25, 2018